BCR-ABL-transformed GMP as myeloid leukemic stem cells

During blast crisis of chronic myelogenous leukemia (CML), abnormal granulocyte macrophage progenitors (GMP) with nuclear β-catenin acquire self-renewal potential and may function as leukemic stem cells (Jamieson et al. N Engl J Med, 2004). To develop a mouse model for CML-initiating GMP, we expressed p210BCR-ABL in an established line of E2A-knockout mouse BM cells that retain pluripotency in ex vivo culture. Expression of BCR-ABL in these cells reproducibly stimulated myeloid expansion in culture and generated leukemia-initiating cells specifically in the GMP compartment. The leukemogenic GMP displayed higher levels of β-catenin activity than either the nontransformed GMP or the transformed nonGMP, both in culture and in transplanted mouse BM. Although E2A-deficiency may have contributed to the formation of leukemogenic GMP, restoration of E2A-function did not reverse BCR-ABL-induced transformation. These results provide further evidence that BCR-ABL-transformed GMP with abnormal β-catenin activity can function as leukemic stem cells.

[1]  T. Reya,et al.  Loss of β-Catenin Impairs the Renewal of Normal and CML Stem Cells In Vivo , 2007 .

[2]  M. Deininger.  Optimizing therapy of chronic myeloid leukemia. , 2007, Experimental hematology.

[3]  M. Duñach,et al.  Bcr‐Abl stabilizes β‐catenin in chronic myeloid leukemia through its tyrosine phosphorylation , 2007, The EMBO journal.

[4]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[5]  F. Lee,et al.  Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice , 2006, Proceedings of the National Academy of Sciences.

[6]  Hiroshi Kawamoto,et al.  E proteins and Notch signaling cooperate to promote T cell lineage specification and commitment , 2006, The Journal of experimental medicine.

[7]  I. Weissman,et al.  The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Hongyue Dai,et al.  Gene expression changes associated with progression and response in chronic myeloid leukemia. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[9]  B. Druker,et al.  Targeted CML therapy: controlling drug resistance, seeking cure. , 2006, Current opinion in genetics & development.

[10]  Karin Moelling,et al.  Bcr is a negative regulator of the Wnt signalling pathway , 2005, EMBO reports.

[11]  R. Cardiff,et al.  Tumor promotion by caspase-resistant retinoblastoma protein , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[12]  R. Ren,et al.  Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia , 2005, Nature Reviews Cancer.

[13]  K. Akashi,et al.  MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. , 2004, Cancer cell.

[14]  Laurie E Ailles,et al.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. , 2004, The New England journal of medicine.

[15]  Hiroshi Kawamoto,et al.  Long-term cultured E2A-deficient hematopoietic progenitor cells are pluripotent. , 2004, Immunity.

[16]  Irving L Weissman,et al.  Biology of hematopoietic stem cells and progenitors: implications for clinical application. , 2003, Annual review of immunology.

[17]  C. Sawyers,et al.  Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias , 2003, Oncogene.

[18]  T. Naoe,et al.  Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. , 2003, Blood.

[19]  J. Melo,et al.  Chronic myeloid leukemia--advances in biology and new approaches to treatment. , 2003, The New England journal of medicine.

[20]  I. Weissman,et al.  Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  C. Murre,et al.  E-proteins directly regulate expression of activation-induced deaminase in mature B cells , 2003, Nature Immunology.

[22]  R. Ren.  The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model , 2002, Oncogene.

[23]  H. Saito,et al.  Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors , 2002, Leukemia.

[24]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[25]  P. Vigneri,et al.  Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR–ABL tyrosine kinase , 2001, Nature Medicine.

[26]  I. Weissman,et al.  Development of CD8α-Positive Dendritic Cells from a Common Myeloid Progenitor , 2000 .

[27]  I. Weissman,et al.  A clonogenic common myeloid progenitor that gives rise to all myeloid lineages , 2000, Nature.

[28]  X Zhang,et al.  Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. , 1998, Blood.

[29]  T. Reya,et al.  Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. , 2007, Cancer cell.

[30]  C. Sawyers,et al.  Targeted cancer therapy , 2004, Nature.

[31]  I. Weissman,et al.  Development of CD8alpha-positive dendritic cells from a common myeloid progenitor. , 2000, Science.